---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-23-000022"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2023-08-01T23:59:59+00:00"
generated_at: "2026-06-12T21:05:14.245640+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Incyte Q2 product revenue up 25% to $827M; raises Jakafi guidance; CSO departs

## Summary
- Total net product revenue $827M (+25% YoY); Jakafi $682M (+14%), Opzelura $80M (+384%).
- Raises Jakafi FY 2023 revenue guidance low end to $2.58-2.63B (from $2.55-2.63B).
- Two pivotal trials met endpoints: ruxolitinib cream in pediatric AD (TRuE-AD3) and axatilimab in chronic GVHD (AGAVE-201).
- CSO Dr. Dashyant Dhanak leaving effective Aug 2, 2023; oversaw 15+ IND filings during tenure.

## SEC filing metadata
- accession: 0000879169-23-000022
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2023-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/0000879169-23-000022-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/incy-20230801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-23-000022
- JSON: https://secwatch.observer/filing/0000879169-23-000022.json
- Plain text: https://secwatch.observer/filing/0000879169-23-000022.txt

## Key facts
- Earnings Releases
  INCYTE CORP reported second fiscal quarter ended June 30, 2023 results: revenue Total net product revenues of $827 million in the second quarter (Q2'23). Guidance raised.
  - Period: second fiscal quarter ended June 30, 2023
  - Revenue: Total net product revenues of $827 million in the second quarter (Q2'23)
  - Guidance: raised
  - Result: reported results
  source text: Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs – Total net product revenues of $827 million in the second quarter (Q2'23) (+25% Y/Y) – Jakafi ® (ruxolitinib) net product revenues of $682 million (+14% Y/Y) in Q2'23; raising the bottom end of full year guidance to a new range of $2.58 - $2.63 billion for FY 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/879169/000087916923000022/0000879169-23-000022-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.